Everand Logo

Welcome to Everand!

  • Discover millions of ebooks, audiobooks, and so much more with a free trial

    Only $11.99/month after trial. Cancel anytime.

    Small Molecules in Oncology
    Small Molecules in Hematology
    Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer
    Ebook series5 titles

    Recent Results in Cancer Research Series

    By Uwe M. Martens and Michail Ignatiadis

    ()

    About this series

    This book presents in detail the problems and ethical challenges in daily oncological practice. 

    In western industrialized countries, roughly 25 percent of all citizens still die from cancer. Despite significant progress in basic science and in individual areas of clinical care, even in the 21st century, being diagnosed with cancer has lost none of its dread and can still be a death sentence. This situation raises many problems and challenges for medical ethics, e.g., the question of the benefits and risks of prevention programs, or the right to know and not to know. 

    Clinical trials with cancer patients and quality assurance for surgery, radiotherapy and medication also pose a series of ethical dilemmas. Furthermore, cancer treatment is a psychological challenge not only for patients but also for physicians and caregivers. The issues of adequate pain management and good palliative care, of treatment limiting and the question of assisted suicide at the end of life also have to be considered. In order to reflect the subject’s diverse and multifaceted nature, the book incorporates legal, ethnographic, historical and literary perspectives into ethical considerations.


    LanguageEnglish
    PublisherSpringer
    Release dateJan 1, 1996
    Small Molecules in Oncology
    Small Molecules in Hematology
    Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

    Titles in the series (5)

    • 195

      Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer
      Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

      Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

      Michail Ignatiadis
      0 ratings
      0 ratings

      This important book provides up-to-date information on a series of topical issues relating to the approach to minimal residual disease in breast cancer patients. It first explains how the study of minimal residual disease and circulating and disseminated tumor cells (CTCs/DTCs) can assist in the understanding of breast cancer metastasis. A series of chapters then discuss the various technologies available for the detection and characterization of CTCs and DTCs, pinpointing their merits and limitations. Detailed consideration is given to the relevance of CTCs and DTCs, and their detection, to clinical research and practice. The role of other blood-based biomarkers is also addressed, and the closing chapters debate the challenges facing drug and biomarker co-development and the use of CTCs for companion diagnostic development. This book will be of interest and assistance to all who are engaged in the modern management of breast cancer.

      This important book provides up-to-date information on a series of topical issues relating to the approach to minimal residual disease in breast cancer patients. It first explains how the study of minimal residual disease and circulating and disseminated tumor cells (CTCs/DTCs) can assist in the understanding of breast cancer metastasis. A series of chapters then discuss the various technologies available for the detection and characterization of CTCs and DTCs, pinpointing their merits and limitations. Detailed consideration is given to the relevance of CTCs and DTCs, and their detection, to clinical research and practice. The role of other blood-based biomarkers is also addressed, and the closing chapters debate the challenges facing drug and biomarker co-development and the use of CTCs for companion diagnostic development. This book will be of interest and assistance to all who are engaged in the modern management of breast cancer.

    • 211

      Small Molecules in Oncology
      Small Molecules in Oncology

      Small Molecules in Oncology

      Uwe M. Martens
      0 ratings
      0 ratings

      This book, written by respected experts, discusses in detail the latest developments in targeted oncology therapy using small molecules. It covers a wide range of small molecules, including tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase inhibitors, as well as cell cycle and NTRK interacting agents. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.  Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book is the third edition of Small Molecules in Oncology, but has now been divided into two volumes, with the other volume focusing specifically on small molecules in hematology. 

      This book, written by respected experts, discusses in detail the latest developments in targeted oncology therapy using small molecules. It covers a wide range of small molecules, including tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase inhibitors, as well as cell cycle and NTRK interacting agents. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.  Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book is the third edition of Small Molecules in Oncology, but has now been divided into two volumes, with the other volume focusing specifically on small molecules in hematology. 

    • 212

      Small Molecules in Hematology
      Small Molecules in Hematology

      Small Molecules in Hematology

      Uwe M. Martens
      0 ratings
      0 ratings

      This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.  Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title. 

      This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.  Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title. 

    • 215

      Tumor Liquid Biopsies
      Tumor Liquid Biopsies

      Tumor Liquid Biopsies

      Florence Schaffner
      0 ratings
      0 ratings

      This book is a comprehensive guide to the techniques, clinical applications, and benefits of the different forms of liquid biopsy employed in patients with a variety of tumor types, including lung, breast and colorectal cancer. Offering detailed explanations, it discusses the how changes in tumors can be tracked using these cutting-edge technologies, which enable the detection and analysis of diverse circulating biomarkers: tumor cells, tumor DNA, tumor RNA (free or in exosomes), and fluid biomarkers identifiable by means of targeted proteomics. The use of such advanced technologies is enabling us to tackle questions and problems in a way that was not possible just a few years ago. We now have at our disposal an effective means of overcoming the problem of intratumor heterogeneity, which has limited the value of conventional biopsy approaches. As a consequence, oncology practice is about to change radically, toward truly personalized precision medicine. This book provides both clinicians and researchers with a thorough and up-to-date overview of progress in the field.

      This book is a comprehensive guide to the techniques, clinical applications, and benefits of the different forms of liquid biopsy employed in patients with a variety of tumor types, including lung, breast and colorectal cancer. Offering detailed explanations, it discusses the how changes in tumors can be tracked using these cutting-edge technologies, which enable the detection and analysis of diverse circulating biomarkers: tumor cells, tumor DNA, tumor RNA (free or in exosomes), and fluid biomarkers identifiable by means of targeted proteomics. The use of such advanced technologies is enabling us to tackle questions and problems in a way that was not possible just a few years ago. We now have at our disposal an effective means of overcoming the problem of intratumor heterogeneity, which has limited the value of conventional biopsy approaches. As a consequence, oncology practice is about to change radically, toward truly personalized precision medicine. This book provides both clinicians and researchers with a thorough and up-to-date overview of progress in the field.

    • 218

      Ethical Challenges in Cancer Diagnosis and Therapy
      Ethical Challenges in Cancer Diagnosis and Therapy

      Ethical Challenges in Cancer Diagnosis and Therapy

      Axel W. Bauer
      0 ratings
      0 ratings

      This book presents in detail the problems and ethical challenges in daily oncological practice.  In western industrialized countries, roughly 25 percent of all citizens still die from cancer. Despite significant progress in basic science and in individual areas of clinical care, even in the 21st century, being diagnosed with cancer has lost none of its dread and can still be a death sentence. This situation raises many problems and challenges for medical ethics, e.g., the question of the benefits and risks of prevention programs, or the right to know and not to know.  Clinical trials with cancer patients and quality assurance for surgery, radiotherapy and medication also pose a series of ethical dilemmas. Furthermore, cancer treatment is a psychological challenge not only for patients but also for physicians and caregivers. The issues of adequate pain management and good palliative care, of treatment limiting and the question of assisted suicide at the end of life also have to be considered. In order to reflect the subject’s diverse and multifaceted nature, the book incorporates legal, ethnographic, historical and literary perspectives into ethical considerations.

      This book presents in detail the problems and ethical challenges in daily oncological practice.  In western industrialized countries, roughly 25 percent of all citizens still die from cancer. Despite significant progress in basic science and in individual areas of clinical care, even in the 21st century, being diagnosed with cancer has lost none of its dread and can still be a death sentence. This situation raises many problems and challenges for medical ethics, e.g., the question of the benefits and risks of prevention programs, or the right to know and not to know.  Clinical trials with cancer patients and quality assurance for surgery, radiotherapy and medication also pose a series of ethical dilemmas. Furthermore, cancer treatment is a psychological challenge not only for patients but also for physicians and caregivers. The issues of adequate pain management and good palliative care, of treatment limiting and the question of assisted suicide at the end of life also have to be considered. In order to reflect the subject’s diverse and multifaceted nature, the book incorporates legal, ethnographic, historical and literary perspectives into ethical considerations.

    Related to Recent Results in Cancer Research

    Related ebooks

    Medical For You

    View More
    View More

    Related podcast episodes

    Related categories

    Reviews for Recent Results in Cancer Research

    0 ratings

    0 ratings0 reviews

    What did you think?

    Tap to rate

    Review must be at least 10 words